Financial analysis of alternative treatments for clinical mastitis associated with environmental pathogens.
For two large California dairy herds with twice daily milking, 171 infected quarters of lactating cows with mild clinical mastitis were randomly assigned to one of three treatment groups. Group A (50 cows) was treated with 62.5 mg of intramammary amoxicillin every 12 h for three milkings. Group C (50 cows) was treated with 200 mg of intramammary cephapirin every 12 h for two milkings. Group O (71 cows) was treated with 100 U of intramuscular oxytocin every 12 h for three milkings. Clinical cure rates did not differ among treatment groups. The cost per episode of clinical mastitis was higher ($54.47) for group C than for groups A ($38.53) or O ($34.88). Group O had a higher incidence of relapse (41%), and a greater percentage of group O cows (65%) experienced an additional mastitic event in the enrolled lactation than did cows in groups A and C. Treatment had no effect on the mean number of nonsalable milkings (24.7) associated with mastitis in the lactation interval subsequent to enrollment on the trial. Twenty-two percent of the cows accrued more than 30 nonsalable milkings and produced 55% of the total nonsalable milkings associated with mastitis. There was no treatment effect on total milk production, fat production, or time to removal of the enrolled cows from the herd.
Van Eenennaam
A L
AL
University of California, Davis 95616, USA.
Gardner
I A
IA
Holmes
J
J
Perani
L
L
Anderson
R J
RJ
Cullor
J S
JS
Guterbock
W M
WM
D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002417:Cattle; D002511:Cephalosporins / Q000627:therapeutic use; D002514:Cephapirin / Q000008:administration & dosage / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003612:Dairying / Q000191:economics*; D005260:Female; D007774:Lactation; D008321:Mammary Glands, Animal; D008414:Mastitis, Bovine / Q000188:drug therapy* / Q000191:economics* / Q000382:microbiology; D010121:Oxytocin / Q000008:administration & dosage / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D012008:Recurrence
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D010121:Oxytocin; D000658:Amoxicillin; D002514:Cephapirin